Merck News (NYSE:MRK)

DateTimeSource
Headline
12/14/20174:45PMBWMerck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastr...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-061 trial investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, did... More...>>
12/14/20171:20PMPRNCAPREVYMIS™ (létermovir) offert au Canada à la fin décembre 2017 pour la prophylaxie d'une infection à cytomégalovirus (...
PREVYMIS™ (létermovir) offert au Canada à la fin décembre 2017 pour la prophylaxie d'une infection à cytomégalovirus (CMV) chez les adultes séropositifs pour le CMV ayant reçu une greffe de cellules souches hématopoïétiques allogénique Canada NewsWire KIRKLAND... More...>>
12/14/20171:19PMPRNCAPREVYMIS™ (letermovir) Available in Canada in Late December 2017 for the Prophylaxis of Cytomegalovirus (CMV) Infection in ...
PREVYMIS™ (letermovir) Available in Canada in Late December 2017 for the Prophylaxis of Cytomegalovirus (CMV) Infection in Adult CMV-seropositive Recipients of an Allogeneic Hematopoietic Stem Cell Transplant Canada NewsWire KIRKLAND, QC, Dec. 14, 2017 KIRKLAND, QC, Dec. 14, 2017 /CNW Telbec/ - Merck & Co... More...>>
12/11/20176:30AMBWFDA Accepts Supplemental Biologics License Application (sBLA), Assigns Priority Review to Merck’s KEYTRUDA® (pembrolizumab...
Data for KEYTRUDA in Patients with Relapsed or Refractory PMBCL Show Overall Response Rate of 41 Percent in Difficult-to-Treat Patient Population Findings from KEYNOTE-170 Presented at 59th American Society of Hematology (ASH) Annual Meeting Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced... More...>>
12/06/20175:02PMBWNew England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS™ (letermovir), Merck’s New CMV Prophylaxis M...
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS™ (letermovir), the company’s new medicine for prophylaxis (prevention) of cytomegalovirus... More...>>
11/30/20179:00AMBWMerck Commemorates 30 Years of MECTIZAN® Donation Program Progress
Program Expanded to Reach Additional 100 Million People Annually for Lymphatic Filariasis in Support of New, Evidence-Based WHO Guidelines Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an expansion of the MECTIZAN® Donation Program (MDP) to reach up to an additional 100 million people... More...>>
11/30/20177:00AMBWNew & Updated Data for Merck’s KEYTRUDA® (pembrolizumab) & Updated Data on LYNPARZA® (olaparib) in Multiple Breast Cancer...
Efficacy Data from Phase 2 KEYNOTE-086 Trial, Cohort B, for KEYTRUDA Monotherapy in Patients with Untreated Metastatic Triple-Negative Breast Cancer to Be Featured in Spotlight Session Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data from six abstracts investigating... More...>>
11/29/20177:00AMBWImpassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Dis...
A vivacious working mother. A motivated college athlete. A career-minded dad and avid runner. An energetic father and professional soccer referee. They differ in age, gender, athleticism and careers, yet each was stunned by a lung cancer diagnosis. Today, the four lung cancer survivors take every opportunity to... More...>>
11/28/20172:33PMBWMerck Announces Increased Quarterly Dividend and $10 Billion Share Repurchase Authorization
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.48 per outstanding share of the company’s common stock, up $0.01 from $0.47 per outstanding share paid last quarter. Payment will be made on Jan. 8... More...>>
11/15/20172:51PMDJNGates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases
By Peter Wonacott in Abu Dhabi and Betsy McKay in Atlanta To tackle dangerous but curable tropical diseases in poor countries, the global health community is following the money -- increasingly to the Persian Gulf. On Wednesday, the Crown Prince of Abu Dhabi, Sheikh Mohamed bin Zayed Al Nahyan launched a fund with the... More...>>
11/14/20176:55AMBWMerck Announces Final Results of Any and All Tender Offers
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed in the table below (collectively, the “Notes”). On Nov. 6, 2017, Merck commenced the Offers... More...>>
11/13/20172:00PMBWMerck Announces Pricing of Any and All Tender Offers
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, announced today the pricing of the previously announced offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed in the table below (collectively, the “Notes”). The Offers are being made upon... More...>>
11/13/20178:00AMBWMerck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PREVYMIS™ (letermovir) for prophylaxis of cytomegalovirus (CMV) reactivation... More...>>
11/09/20176:45AMBWMerck Receives FDA Approval of PREVYMIS™ (letermovir) for Prevention of Cytomegalovirus (CMV) Infection & Disease in Adult ...
CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause Mortality Through Week 24 and Week 48 Post-Transplant Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS™ (letermovir) once-daily tablets... More...>>
11/07/20174:00AMPRNCAMerck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years
Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years Canada NewsWire DARMSTADT, Germany, Nov. 7, 2017 New whitepaper from Consumer Health business shines light on preparing the young generation for living 100 healthy years Whitepaper focuses on the importance to adopt good health habits early... More...>>
11/06/20175:00PMBWMerck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Animated Duo, Sugar & Spike Educate Pet Owners on Diabetes Recognition, Diagnosis and Management November is Pet Diabetes Month, and to raise awareness of diabetes in pets, Merck Animal Health (known as MSD Animal Health outside the United States and Canada) has launched Care & Control of Pet Diabetes Featuring... More...>>
11/06/20178:56AMBWMerck Announces Any and All Tender Offers
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today the commencement of offers to purchase (collectively, the “Offers”) any and all of the outstanding notes listed in the table below (collectively, the “Notes”). The Offers are being made upon, and are subject to, the terms and conditions... More...>>
11/06/20178:30AMGLOBEBriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 06, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its ongoing Phase I/IIa study... More...>>
11/02/20171:18PMBWKILL Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Merck Animal Health requests that their press release NewsItemId 20171101005509, (issued Nov.1, 2017) entitled “Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease” be killed. The release was issued prematurely by Merck Animal Health. View source version on businesswire.com:... More...>>
11/02/20179:00AMBWMerck Publishes Annual Corporate Responsibility Report
Report Highlights New Environmental Sustainability Goals and Impact on Global Health Merck (NYSE:MRK), known as MSD outside the United States and Canada, today published its 2016/2017 Corporate Responsibility Report. The report reflects the company’s performance in the areas of Access to Health, Employees, Environmental... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20171215 10:20:14